Unlike other new therapeutics, cannabis-based medicines include an unparalleled diversity of ‘unknown’ products – comprising a wide range of formulations for use in the treatment of a broad range of conditions.

There is an immediate requirement for quality information and guidance for prescribers. And, for well-informed government regulation and policy.

As an emerging class of medicines, the safe introduction and long term use of cannabinoids depends on:

  • effective prescribing, dispensing, and administration
  • focused clinical and scientific research supporting medicine development
  • workable Government policy and regulations
  • active support for pharmacovigilance activities